Idorsia Ltd announces the initial findings of REACT, a Phase III study which investigated the efficacy and safety of clazosentan in preventing clinical deterioration due to delayed cerebral ischemia, in patients following aneurysmal subarachnoid hemorrhage (aSAH)
Iorsia Ltd and Idorsia Pharmaceuticals Japan announced that the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has approved Pivlaz (clazosentan sodium) 150 mg, a selective endothelin A (ETA) receptor antagonist, for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage (aSAH).
Boston Scientific Corporation announced the launch of the Resolution 360 Clip, a novel technology designed to improve hemostatic clipping by...
Background: We analyze our experience of using TachoSil® (Takeda Austria GmbH: Linz, Austria) in microneurosurgical procedures as a hemostat and also as a sealant to patch dural defects.
Reduction of intraocular pressure (IOP) is the only reliable treatment for glaucoma that maintains the patient's visual function throughout life, and IOP-lowering eyedrops are the mainstay of therapy.
Background: The safety and efficacy of doravirine were compared with that of efavirenz as initial treatment of adults living with HIV-1 infection.
MMI SpA,(Medical Microinstruments S.P.A.) an Italian company dedicated to improving clinical outcomes for patients undergoing microsurgery, announced the CE Mark, launch and first human use of its Symani Surgical System in Europe for open microsurgical procedures.
The FDA Circulatory System Devices Panel of the Medical Devices Advisory Committee has on 20 March 2013, voted by majority...
The twelve recommendations are intended to advise physicians on the use of imaging modalities when making a clinical diagnosis, and when to apply imaging for monitoring of disease activity and damage.